timothy sykes logo

Stock News

Genmab Eyes Merus: Market Awaits Possible Acquisition

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Updated 9/29/2025, 9:19 am ET 9/29/2025, 9:19 am ET | 5 min 5 min read
Genmab Eyes Merus: Market Awaits Possible Acquisition Thumbnail

Merus N.V. stocks have been trading up by 37.19% amid FDA designations and promising research advancements.

Candlestick Chart

Live Update At 09:18:40 EST: On Monday, September 29, 2025 Merus N.V. stock [NASDAQ: MRUS] is trending up by 37.19%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Earnings and Financial Snapshot

As successful trading often hinges on the mindset and strategies applied, many experts emphasize the importance of emotional discipline and tactical approaches. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” This quote encapsulates a core trading philosophy that can help traders manage their activities. It suggests that in order to achieve long-term success in trading, one should minimize losses swiftly, allow successful trades to reach their potential, and avoid excessive trading that can lead to poor decision-making. Such principles serve as valuable guidance for traders aiming to navigate the complex dynamics of the trading world effectively.

Merus is riding a roller coaster in the financial market. In its most recent quarterly results, the company reported total revenue just shy of $8.9M, with gross profit also matching the revenue, suggesting tight margins. Despite its efforts, the operating income fell into the negatives, standing at a loss of over $110M. The widening gap between high operating expenses and revenue reveals a challenging path.

Key ratios paint Merus in intriguing colors; an ebit margin resting at a troubling -591% and a debt-to-equity showing a modest 0.01 ratio offer a glimpse into the financial stability and operational hurdles it faces. With a current ratio of 8.4, Merus possesses a significant buffer for meeting short-term liabilities, indicating strong liquidity.

From the balance sheet, total assets amounting to approximately $980M include a hefty $710M in cash and cash equivalents, providing substantial cushioning. Despite total liabilities approaching $138M, Merus’s stockholders’ equity stands firm at around $842M.

Insights from Recent Trading

Looking into the recent trading sessions, Merus shares have been riding small waves but remained fairly stable overall. Between Sep 19 and Sep 28, the ebbs and flows were marked by a decent high at $70.38 and a low at $65.61, but closed at $68.89. This motion underscores investor hesitancy amid acquisition rumors and market uncertainties.

Nimble maneuvers in these trading sessions saw the stock not breaking major levels, but staying within margins that reflect caution. Intraday moves highlighted modest fluctuations—a sign traders perhaps await concrete acquisition news without making precipitous decisions.

More Breaking News

The Path Ahead

The rumored acquisition by Genmab entices traders and market-watchers, setting the stage for what could be a significant financial tango. Merus’s innovative strides in cancer treatment research offer promising returns, potentially enticing Genmab to secure a foothold in cutting-edge oncology therapies. Analyst enthusiasm, given Barclays’ “Overweight” rating, can further bolster trader morale, yet the impending acquisition remains pivotal.

For shareholders, the probable acquisition by Genmab might spell lucrative returns if the premium proves attractive. However, it also brings uncertainty and volatility, requiring shrewd assessment in the upcoming weeks. As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” This reminder is crucial, as the trading landscape is often rife with opportunities and the importance of strategic patience cannot be overemphasized.

Despite current challenges, Merus’s research initiatives and advancements in petosemtamab indicate a future increasingly tethered to potential breakthroughs in spaces critical to modern healthcare needs.

In summary, as the market tunes into the outcome of Genmab’s move, Merus continues to operate in a realm brimming with potential, uncertainties, and waves of speculative buzz.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”